Loading
Life sciences · Journal article
Acs Applied Materials & Interfaces · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Proteolysis-targeting chimeras (PROTACs) are a promising therapeutic approach for degrading disease-causing proteins. However, they often encounter limitations in in vivo applications due to poor solubility, low cellular permeability, unfavorable pharmacokinetics, and more. To address these challenges, we developed a multifunctional “onion-like” nanoplatform, PB@SiO2@MnO2@dGPX4/PVP (PMDP), which delivers a glutathione peroxidase 4 (GPX4) PROTAC degrader, dGPX4, to induce ferroptosis in triple-negative breast cancer cells. PMDP consists of Prussian blue (PB) nanoparticles that are coated with a protective SiO2 layer and an MnO2 shell. The nanoparticles are encapsulated with polyvinylpyrrolidone after dGPX4 adsorbs onto the surface. The resulting PMDP enhances tumor enrichment and cellular uptake of dGPX4. It also depletes glutathione and catalyzes Fenton-like reactions in cancer cells, generating reactive oxygen species (ROS). PB’s near-infrared (NIR) photothermal capability simultaneously facilitates this reaction and enables mild photothermal therapy. Concurrently, dGPX4 effectively degrades the key anti-ferroptosis protein GPX4, thereby disrupting the cellular antioxidant defense system. Studies demonstrate that PMDP induces a “ROS storm”, lipid peroxidation, and mitochondrial damage, triggering efficient ferroptosis and significantly inhibiting tumor growth in TNBC models. This research shows the potential to integrate targeted protein degradation with multiple nanomedicine technologies, offering a promising combination strategy for cancer therapy.